Emerging protein kinase inhibitors for non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Precision medicine in non-small cell lung cancer (NSCLC) relies on molecular characteristics for treatment.
• Kinase inhibitors targeting EGFR mutations or ALK rearrangements exemplify this precision approach.
• Emerging kinase inhibitors offer potential for improved treatment of NSCLC genomic subtypes.

Purpose of the Study:

• To review next-generation kinase inhibitors for EGFR and ALK-positive NSCLC.
• To cover targeted kinase inhibitors in development for other NSCLC molecular subtypes.
• To provide expert opinion on the current and future role of kinase inhibitors in NSCLC treatment.

Main Methods:

• Review of next-generation kinase inhibitors targeting EGFR and ALK in NSCLC.
• Inclusion of kinase inhibitors in clinical development for ROS1, BRAF, RET, HER2, KRAS, MET, PIK3CA, FGFR1, DDR2, VEGFR, and AAK.
• Analysis of current evidence and ongoing trials for kinase inhibitor efficacy.

Main Results:

• Several kinase inhibitors demonstrate promising activity in EGFR-mutant NSCLC, including dacomitinib and CO-1686 for acquired resistance.
• Next-generation ALK inhibitors show greater potency than crizotinib.
• Ongoing trials will clarify the role of ALK and ROS1 inhibitors.

Conclusions:

• Promising kinase inhibitors exist for EGFR-mutant NSCLC, particularly for acquired resistance.
• Next-generation ALK inhibitors are more potent than crizotinib.
• While optimistic for other subtypes, more evidence from prospective trials is required for recommendations.